SuperworthMerck & Co., Inc. MRK
Drug Manufacturers - General, Healthcare
$142.79
+0.60%
- Market cap
- $352.3B
- PE
- 114×
- 10y median 25.7×
- Forward PE
- Price to sales
- 5.3×
- EV/EBIT
- 20.1×
- Revenue, 12 months
- $66.6B
- +5% on a year ago
- Net margin
- 4.8%
- Free cash flow yield
- 4.6%
Merck trades at 114× trailing earnings, pricier than 91% of the last ten years. Revenue was $66.6B over the last twelve months, up 5% on a year earlier with a 5% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $14.6B | $15.8B | $16.1B | $16.7B | $15.6B+7% | $15.5B−2% | $15.8B−2% | $17.3B+4% | $16.4B+5% | $16.3B+5% | $16.6B+5% | |
| Cost of revenue | $3.9B | $3.5B | $3.7B | $4.1B | $3.8B−2% | $3.4B−3% | $3.6B−5% | $3.9B−6% | $5.6B+45% | $4.2B+23% | $4.4B+24% |
| Gross profit | $10.7B | $12.2B | $12.4B | $12.6B | $11.8B+10% | $12.1B−1% | $12.2B−1% | $13.4B+7% | $10.8B−8% | $12.1B−0% | $12.2B−0% |
| R&D | $9.6B | $4B | $3.5B | $5.9B | $4.6B−52% | $3.6B−9% | $4B+16% | $4.2B−28% | $3.9B−15% | $12.6B+248% | $9.7B+141% |
| SG&A | $2.8B | $2.5B | $2.7B | $2.7B | $2.9B+2% | $2.6B+3% | $2.6B−3% | $2.6B−4% | $2.9B+1% | $2.7B+6% | $2.9B+10% |
| −$1.7B | $5.8B | $6.1B | $4B | $4.3B | $6.7B+17% | $6.4B+4% | $7.5B+87% | $6.2B+42% | −$1.9B | −$683M | |
| Interest expense | $310M | $303M | $310M | $330M | $328M+6% | $313M+3% | $305M−2% | $327M−1% | $411M+25% | $0 | $525M+72% |
| Pre-tax income | −$2B | $5.7B | $6B | $4.1B | $4.2B | $5.9B+4% | $5B−17% | $6.7B+65% | $3.4B−18% | −$3.5B | −$683M |
| −$820M | $903M | $545M | $929M | $426M | $818M−9% | $571M+5% | $958M+3% | $458M+8% | $709M−13% | $654M+15% | |
| Net income | −$1.2B | $4.8B | $5.5B | $3.2B | $3.7B | $5.1B+7% | $4.4B−19% | $5.8B+83% | $3B−21% | −$4.2B | −$1.3B |
| −$0.48 | $1.87 | $2.14 | $1.24 | $1.48 | $2.01+8% | $1.76−18% | $2.32+87% | $1.19−20% | −$1.72 | −$0.54 | |
| 2.6B | 2.5B | 2.5B | 2.5B | 2.5B−1% | 2.5B−1% | 2.5B−1% | 2.5B−2% | 2.5B−2% | 2.5B−2% | 2.5B−2% |
From each company's 10-Q and 10-K filings. Fiscal years are four fiscal quarters added up; balance sheet lines are as of the period's end. Growth is on the same period a year earlier.
Estimates
Next earnings report: .
Analyst consensus for the next eight quarters, with the range from the lowest to the highest estimate, is part of Superworth Pro.
Peers
Companies in Drug Manufacturers - General within ten times Merck's size, closest in size first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| MRKMerck & Co., Inc. | $352.3B | 114× | 25.7× | 5.3× | +5% | 4.8% | |
| ABBVAbbVie Inc. | $479.5B | 76.7× | 27.5× | 7.4× | +10% | 9.8% | |
| AMGNAmgen Inc. | $223.3B | 25.7× | 21.0× | 5.9× | +9% | 23.0% | |
| JNJJohnson & Johnson | $622.8B | 29.9× | 24.2× | 6.4× | +8% | 21.5% | |
| PFEPfizer Inc. | $159.6B | 36.8× | 16.3× | 2.5× | −0% | 6.8% | |
| BMYBristol-Myers Squibb Company | $122B | 13.1× | 19.9× | 2.5× | +3% | 18.9% | |
| LLYEli Lilly and Company | $1.1T | 39.9× | 41.3× | 14.0× | +50% | 33.5% | |
| Peer median | $351.4B | 33.4× | 22.6× | 6.1× | +9% | 20.2% |
About
- Chief executive
- Rob Davis, since 2021Joined 2014 as CFO, CEO since 2021. Source
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .